Related Experiment Video
Updated: Jul 19, 2026
09:44
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
Published on: January 29, 2019
Current status and perspectives in alpha radioimmunotherapy.
M Chérel1, F Davodeau, F Kraeber-Bodéré
1Department of Cancerology, University of Nantes, INSERM U601, Nantes, France. mcherel@nantes.inserm.fr
Summary
Alpha radioimmunotherapy (RIT) shows promise for cancer treatment, offering targeted cell destruction. Further research is needed to optimize radiolabeling and administration for enhanced efficacy and safety.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiopharmaceutical Science
Background:
- Radioimmunotherapy (RIT) uses radiolabeled antibodies to target cancer cells.
- Beta-emitting radionuclides are effective in treating hematological cancers via RIT.
- Alpha-emitting radionuclides are emerging as a promising alternative for RIT due to their unique physical properties.
Purpose of the Study:
- To explore the potential of alpha-emitting radionuclides in radioimmunotherapy (RIT).
- To address the challenges in the preclinical development of alpha-RIT.
- To define optimal therapeutic strategies for alpha-RIT, including combination treatments.
Main Methods:
- Review of current RIT strategies and the characteristics of alpha emitters.
- Discussion of challenges in radiolabeling, in vivo stability, and administration of alpha-RIT agents.
- Analysis of cellular and tissue responses to alpha irradiation for therapeutic optimization.
Main Results:
- Alpha particles offer a short path length and high linear energy transfer, distinct from beta particles.
- Optimization of radiolabeling methods and in vivo stability is crucial for alpha-RIT.
- Further investigation into radionuclide decay schemes and toxicity is required.
- Improved administration techniques are needed to enhance tumor targeting and dose delivery.
- Alpha-RIT shows potential for synergistic effects with other cancer treatments like chemotherapy.
Conclusions:
- Alpha-RIT is a promising preclinical strategy for cancer therapy, complementary to beta-RIT.
- Addressing technical challenges in radiolabeling, stability, and administration is key to clinical translation.
- Understanding cellular responses to alpha irradiation will guide the development of effective combination therapies for improved antitumor response and organ protection.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:28Isotopes and Radioisotopes
In the early 1900s, English chemist Frederick Soddy realized that an element could have atoms with different masses that were chemically indistinguishable. These different types are called isotopes — atoms of the same element that differ in mass. Isotopes differ in mass because they have different numbers of neutrons but are chemically identical because they have the same number of protons. Soddy was awarded the Nobel Prize in Chemistry in 1921 for this discovery.
An isotope containing more...
An isotope containing more...
03:23Types of Radioactivity
The most common types of radioactivity are α decay, β decay, γ decay, neutron emission, and electron capture.
Alpha (α) decay is the emission of an α particle from the nucleus. For example, polonium-210 undergoes α decay:
Alpha (α) decay is the emission of an α particle from the nucleus. For example, polonium-210 undergoes α decay:
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...